For a manufacturing facility that must maintain one active pharmaceutical ingredient across seven finished dosage-form routes, Sanxiang Powder Veterinary Grade API is specified as the common crystalline powder for tablets, injections, capsules, powders, granules, premix, and solutions. The product model designation is the full trade name “Sanxiang Powder Veterinary Grade API”; no separate numerical model code is published in the current pharmacopoeial cross-reference index. The material is not sold as a sterile powder; injectable presentations must undergo subsequent sterilization by aseptic filtration or terminal heat treatment only after solution stability data demonstrate degradation below 2.0% at the selected thermal cycle. A representative release specification aligned with ChP 2020, EP 11, and USP–NF 2023 includes loss on drying ≤ 0.5% by EP 2.2.32, residue on ignition ≤ 0.1% by ChP 0841, and heavy metals ≤ 10 ppm by EP 2.4.8 method C. These values are not a certificate of analysis for a specific lot; the manufacturer’s batch-specific CoA should be referenced for actual values.

What release specifications are required for Sanxiang Powder Veterinary Grade API in multi-route use?

Because the powder is used in dry and aqueous processes, the release panel includes identification, purity, particle size, endotoxin, and residual solvent parameters. The following checklist is derived from pharmacopoeial monographs for veterinary substances; where a monograph does not include a veterinary species-specific impurity profile, published data for this specific configuration is limited and the indicated limits should be confirmed by the manufacturer’s certificate of analysis.

Analytical method transfer uses a diode-array HPLC system with a 250 mm × 4.6 mm, 5 µm C18 column and mobile phase flow rate of 1.0 mL/min; column temperature is maintained at 30 °C and injection volume is 10 µL. System suitability requires resolution between the API and the nearest impurity not less than 2.0, tailing factor 0.8–1.5, and relative standard deviation ≤ 1.0% for five replicate injections under USP <621>. If the method is used for veterinary matrices with high lipid content, sample cleanup by solid-phase extraction with C18 cartridges is applied before injection. Stability evaluation should follow VICH GL12, with long-term storage at 25 °C/60% RH and accelerated storage at 40 °C/75% RH.

When the same crystalline powder is transferred across dry granulation, fluid-bed agglomeration, and sterile filtration lines

The critical transfer parameter is the particle size distribution plus the compressibility index. For direct compression, the powder is pre-blended with microcrystalline cellulose and croscarmellose sodium in a diffusion blender at 8–12 rpm for 20 min; compressibility is evaluated by the Hausner ratio and should remain ≤ 1.35 according to USP <616>. Batch-to-batch tapped density variation greater than 0.05 g/mL has been associated with weight variation exceeding ±5% on a rotary tablet press operating above 60 rpm; pre-sieving through a 0.5 mm conical mill is therefore required before final blending. For wet granulation, a high-shear mixer with an impeller tip speed of 4–6 m/s and a chopper speed of 1500 rpm produces wet mass with a D50 of 120–180 µm after extrusion through a 1.0 mm screen and fluid-bed drying at 50–60 °C inlet temperature. The dried granulate should attain loss on drying ≤ 2.0% before lubrication with magnesium stearate at 0.5–1.0% w/w. Lubricant levels above 1.0% w/w and blend hold times beyond 30 min are avoided because hydrophobic lubricant film formation can reduce tablet tensile strength; for this API, a lubrication window of 0.5–0.75% w/w is specified.

Injectable solution processing requires the powder to be dissolved in Water for Injection at 20–25 °C under nitrogen blanketing if the API is oxidation-sensitive. The resulting bulk solution is passed through a 0.45 µm prefilter and then a 0.22 µm polyethersulfone or PVDF filter; nylon membranes are avoided because of possible nonspecific adsorption. If terminal sterilization is selected, a cycle of 121 °C for 15 min is permitted only when forced-degradation data demonstrate assay loss below 2.0%; otherwise, aseptic filtration and filling in ISO 5 laminar-flow zones are used. Endotoxin control at ≤ 0.5 EU/mg in the API is not sufficient alone; the finished solution must also meet USP <85> or Ph. Eur. 2.6.14 requirements and particulate matter limits in USP <788> for the chosen container size. The solution pH should be maintained between 3.0 and 6.5 using citrate or acetate buffer; outside this range, precipitation or accelerated degradation may occur.

For multi-species premix, carrier surface properties and segregation control become limiting. The API is typically dispersed onto feed-grade calcium carbonate or lactose carrier at 5–10% w/w; blend uniformity must meet RSD ≤ 5.0% across 10 sampling points per USP <905>. Because density-driven segregation can occur when the API has a Hausner ratio above 1.35, the carrier particle size should be matched within 0.8–1.2 times the API D50. Premix storage above 60% relative humidity has been observed to reduce flowability and increase adhesion to stainless steel transfer lines; pre-drying of the carrier and maintaining packaging headspace relative humidity below 30% are specified operational controls. For oral granules, the milled material is spray-agglomerated in a fluid-bed granulator with inlet air temperature 55–65 °C; the granulated product is dried until loss on drying ≤ 2.0%, then screened through 1.25 mm mesh. Published data for premix recovery in finished feed under commercial manufacturing conditions is limited; a pilot-scale assay recovery study should be executed before bulk production.

Differences from feed-grade and single-dosage-form API powders

The distinction between Sanxiang Powder Veterinary Grade API and feed-grade powders with the same chemical name is documented in the impurity and endotoxin test panel. Feed-grade powder may have a wider particle size distribution and may omit bacterial endotoxin testing; however, injectable and ophthalmic formulations require endotoxin below 0.5 EU/mg and sub-visible particle compliance, which is not a release parameter for feed-grade materials. Single-dosage-form API powders are often optimized for one processing route: direct-compression APIs may be co-processed with excipients or compressed into dense agglomerates that dissolve slowly, while injection-grade APIs are frequently micronized to D90 ≤ 10 µm, which may reduce dry-blend flowability and make tablet die filling inconsistent. Sanxiang Powder Veterinary Grade API at D90 ≤ 75 µm for dry dosage and ≤ 45 µm for parenteral solutions is specified to provide a single stock-keeping unit for both dry and liquid processes, but the dry-grade and injection-grade lots can still be segregated by endotoxin and particle size certification. Buyers should request the injection-grade certificate when the intended route includes parenteral use; the standard dry-grade certificate may not include USP <85> or EP 2.6.14 data.

Packaging for the API consists of double low-density polyethylene bags inside an aluminum foil laminate bag with desiccant. The outer carton is labeled with the product designation “Sanxiang Powder Veterinary Grade API” and the intended dosage-form statement. Storage is at 15–25 °C, protected from light, with warehouse relative humidity below 60%. When the inner bag is opened, the remaining powder should be re-sealed under nitrogen; if ambient relative humidity exceeds 60%, pre-drying at 40–50 °C under vacuum for 2–4 h is specified before use in dry powder formulations. The material is incompatible with strong oxidizing agents; it should not be blended directly with free amines or reducing sugars in aqueous granulation because these components may initiate discoloration or degradation. For injectable formulations, the powder is not sterile and must not be introduced into an aseptic fill line without a validated sterilizing filter. The product is labeled for veterinary drug compounding only and is not intended for human pharmaceutical use.